Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Toby M Maher

Showing results (221-230 of 391) with videos related to

Pageof 40
Sort By:
Thorax|June 10, 2022
Genome-wide association study across five cohorts identifies five novel loci associated with idiopathic pulmonary fibrosisRichard J Allen, Amy Stockwell, Justin M Oldham, et al.
American Journal of Respiratory and Critical Care Medicine|November 23, 2020
Proportion of Idiopathic Pulmonary Fibrosis Risk Explained by Known Common Genetic Loci in European PopulationsOlivia C Leavy, Shwu-Fan Ma, Philip L Molyneaux, et al.
RMD Open|February 16, 2023
Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progressionDinesh Khanna, Toby M Maher, Elizabeth R Volkmann, et al.
Pediatric Pulmonology|January 30, 2024
Estimating the effect of nintedanib on forced vital capacity in children and adolescents with fibrosing interstitial lung disease using a Bayesian dynamic borrowing approachToby M Maher, Kevin K Brown, Steven Cunningham, et al.
BMJ Open Respiratory Research|August 19, 2023
Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF)Luca Richeldi, Arata Azuma, Vincent Cottin, et al.
The European Respiratory Journal|January 9, 2021
Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trialImre Noth, Vincent Cottin, Nazia Chaudhuri, et al.
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|August 1, 2014
Treatment of sarcoidosis-associated pulmonary hypertension: A single centre retrospective experience using targeted therapiesGregory John Keir, Simon L F Walsh, Michael A Gatzoulis, et al.
Respirology (Carlton, Vic.)|December 14, 2017
Likelihood of pulmonary hypertension in patients with idiopathic pulmonary fibrosis and emphysemaJoseph Jacob, Brian J Bartholmai, Srinivasan Rajagopalan, et al.
Chest|October 26, 2021
Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis and COPD: A Propensity-Matched Real-World StudyClaire M Nolan, Oliver Polgar, Susie J Schofield, et al.
The European Respiratory Journal|June 22, 2019
King's Brief Interstitial Lung Disease questionnaire: responsiveness and minimum clinically important differenceClaire M Nolan, Surinder S Birring, Matthew Maddocks, et al.
Pageof 40

Showing results (221-230 of 391) with videos related to

Sort By:
Pageof 40
Thorax|June 10, 2022
Genome-wide association study across five cohorts identifies five novel loci associated with idiopathic pulmonary fibrosisRichard J Allen, Amy Stockwell, Justin M Oldham, et al.
American Journal of Respiratory and Critical Care Medicine|November 23, 2020
Proportion of Idiopathic Pulmonary Fibrosis Risk Explained by Known Common Genetic Loci in European PopulationsOlivia C Leavy, Shwu-Fan Ma, Philip L Molyneaux, et al.
RMD Open|February 16, 2023
Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progressionDinesh Khanna, Toby M Maher, Elizabeth R Volkmann, et al.
Pediatric Pulmonology|January 30, 2024
Estimating the effect of nintedanib on forced vital capacity in children and adolescents with fibrosing interstitial lung disease using a Bayesian dynamic borrowing approachToby M Maher, Kevin K Brown, Steven Cunningham, et al.
BMJ Open Respiratory Research|August 19, 2023
Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF)Luca Richeldi, Arata Azuma, Vincent Cottin, et al.
The European Respiratory Journal|January 9, 2021
Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trialImre Noth, Vincent Cottin, Nazia Chaudhuri, et al.
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|August 1, 2014
Treatment of sarcoidosis-associated pulmonary hypertension: A single centre retrospective experience using targeted therapiesGregory John Keir, Simon L F Walsh, Michael A Gatzoulis, et al.
Respirology (Carlton, Vic.)|December 14, 2017
Likelihood of pulmonary hypertension in patients with idiopathic pulmonary fibrosis and emphysemaJoseph Jacob, Brian J Bartholmai, Srinivasan Rajagopalan, et al.
Chest|October 26, 2021
Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis and COPD: A Propensity-Matched Real-World StudyClaire M Nolan, Oliver Polgar, Susie J Schofield, et al.
The European Respiratory Journal|June 22, 2019
King's Brief Interstitial Lung Disease questionnaire: responsiveness and minimum clinically important differenceClaire M Nolan, Surinder S Birring, Matthew Maddocks, et al.
Pageof 40